Where does Avexxin AS rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Avexxin AS ranks #15,842 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Avexxin AS hold?

Avexxin AS holds 18 US utility patents granted between 2015 and 2023, spanning 4 technology areas.

What is Avexxin AS's Innovation Score?

Avexxin AS has an Innovation Score of 26.6 out of 100 (21st percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Avexxin AS focus on?

Avexxin AS's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 16 patents, ranking #1,230 of 6,058 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is Avexxin AS's patent grant rate increasing or decreasing?

Avexxin AS's recent grant velocity is -36% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Avexxin AS's patents?

Avexxin AS's patents average 10.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Avexxin AS patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Avexxin AS

USPTO PatentsView assignee record - 18 granted patents across 4 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Avexxin ranks #15,842 of 49,997 tracked US assignees by granted-patent volume, with 18 patents across 4 technology areas.

#15,842
of 49,997 US assignees by volume: 21st percentile
by Innovation Score (26.6/100): 10.9
avg claims per patent: -36%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R15842 · Foreign Corporation #15,842 · 18 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 18 grants
MID-PACK #15,842/49,997
PHOTO-FINISH Atturo Tire
CPC-NARROW A61P · 4 areas
INNOV-THIN 26.6/100
CLAIMS-PAR 10.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -36% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Atturo Tire Corp. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Avexxin’s 26.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.2 pts (38%) Velocity 2.9 pts (11%) Breadth 7.1 pts (27%) Claim depth 6.5 pts (24%)

Qualcomm Incorporated · highest

85
Avexxin AS · this assignee

27
3D Lighting… · lowest

7

What this shows Avexxin's Innovation Score is 26.6/100 (21st percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Avexxin?

Each dot is one of Avexxin’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Avexxin’s own 10.9 claims/patent is at or below the 17.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Avexxin vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Avexxin's grants concentrate

Avexxin AS is a focused PatentsView assignee: 4 CPC subclasses with 88.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (4 grants) versus a trough of 1 in 2015. By volume, Avexxin sits between Atturo Tire Corp. and Basf Beauty Care Solutions France SAS.

Avexxin's three-year grant acceleration

Avexxin AS shows 3 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Atturo Tire

18
Auris Surgical Ro…

18
Authentix

18
Avant-garde IP

18
Ayasdi AI

18
B&B Molders

18
B Braun Medical S…

18
Basf Beauty Care…

18
Avexxin AS ◀

18

What this shows Avexxin holds 18 patents at rank #15,844, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Avexxin

By rank, the assignees closest to #15,844 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Avexxin's primary technology class.

Avexxin's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 21st percentile higher than 21% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Avexxin AS patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	5.6%
2016	1	5.6%
2017	2	11.1%
2018	4	22.2%
2019	3	16.7%
2020	2	11.1%
2021	2	11.1%
2022	2	11.1%
2023	1	5.6%

Which technologies does Avexxin AS patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 16

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 14

C07D - Heterocyclic Compounds 8

C07C - Acyclic OR Carbocyclic Compounds 4

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Avexxin AS's patent record in context - here's where to go next.

Avexxin AS's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 88.9% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #15,842 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Avexxin AS against Atturo Tire Corp., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 26.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.